Next Article in Journal / Special Issue
Activity and Export of Engineered Nisin-(1-22) Analogs
Previous Article in Journal
Spontaneous Vesicles Modulated by Polymers
Previous Article in Special Issue
Dark Antimicrobial Mechanisms of Cationic Phenylene Ethynylene Polymers and Oligomers against Escherichia coli
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Polymers
Volume 3
Issue 3
10.3390/polym3031268
polymers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Defensins: Potential Effectors in Autoimmune Rheumatic Disorders

by
Stefan Vordenbäumen
* and
Matthias Schneider
Department of Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Moorenstr. 5, 40225 Düsseldorf, Germany
*
Author to whom correspondence should be addressed.
Polymers 2011, 3(3), 1268-1281; https://doi.org/10.3390/polym3031268
Submission received: 23 June 2011 / Revised: 29 July 2011 / Accepted: 10 August 2011 / Published: 11 August 2011
(This article belongs to the Special Issue Antibacterial Polymers: From Natural Inspiration to Practical Applications)
Versions Notes

Abstract

: Defensins are small cationic peptides with antimicrobial properties. They constitute a highly conserved innate immune defense mechanism across species. Based on the arrangement of disulfide-bonds, α- and β-defensins are distinguished in humans. Both types of defensin comprise several distinct molecules that are preferentially expressed at epithelial surfaces and in blood cells. In the last decade, multiple immunomodulatory functions of defensins have been recognized, including chemotactic activity, the promotion of antigen presentation, and modulations of proinflammatory cytokine secretion. These findings suggested a role for defensins not only as a first line of defense, but also as connectors of innate and adaptive immune responses. Recently, increasingly accumulating evidence has indicated that defensins may also be involved in the pathogenesis of autoimmune rheumatic disorders such as systemic lupus erythematosus and rheumatoid arthritis. The current review summarizes the data connecting defensins to autoimmunity.

1. Review

1.1. Introduction to Defensins

The generation of peptides with antimicrobial properties is a highly conserved mechanism of innate immune defense [1,2]. Across species, over 800 distinct molecules have been included into this group [3,4]. Amongst them, the family of defensins have been identified in nearly all species from plants over insects to higher mammals [2]. Defensins are cationic peptides which contain 12–50 amino acids in length and primarily form β-sheets [1]. In humans, α- and β-defensins are distinguished based on the arrangement of disulfid bonds between their 6 cysteine-residues. While α-defensins display a 1–6, 2–4, 3–5 pattern, β-defensins show a 1–5, 2–4, 3–6 arrangement [5]. So far, 6 oc-defensins and 4 β-defensins have been differentially characterized, but computational genomic analyses have revealed that 28 potential β-defensin genes are present in the human genome [6]. The expression of defensins varies in different tissues, which is thought to reflect microbial challenges at the expression sites [1,2,7]. Human α-defensin 1–4 (commonly referred to as human neutrophil peptides (HNP)) are the major protein species within azurophilic granules of neutrophils, comprising up to 70% of their content [8], while human defensins (hD) 5 and 6 are almost exclusively found in paneth cells of the small intestine [7,9]. Human β-defensins (hBD) are predominantly expressed at epithelial surfaces, but hBD1-4 were also detected in various blood-cells such as monocytes, macrophages and dendritic cells [2,3]. While hBD1 seems to be a constitutively expressed defensin, most other defensins are consistently upregulated by proinflammatory stimuli such as lipopolysaccharides, tumor necrosis factor α (TNFα), and Interleukin-1b (IL1β) [2]. Signal transduction mechanisms were reported to predominantly depend upon nuclear factor κB [3]. All defensins exert antimicrobial effects against a wide range of pathogens including bacteria, fungi, viruses and parasites [3,4]. Their positive charge facilitates association to membranes followed by the generation of pores that disrupt electrolyte homeostasis, thereby leading to cell death [4]. The antimicrobial activity to a certain pathogen varies with each individual defensin [3,4]. Their potent antimicrobial functions and their highly conserved structure across species suggest that the role for defensins initially consisted in direct pathogenic activity. In the evolutionary process, however, this group of peptides has developed additional, i.e. immunomodulatory, functions, a process also known as protein promiscuity [10]. While this review focuses on the potential role of defensins in autoimmune rheumatic disorders, excellent previous reviews cover defensin biology, antimicrobial properties and highlight their various impacts on the immune system [1,2,5,8,11].

1.2. Immunomodulatory Effect of Defensins

Defensins modulate both adaptive and innate immune mechanisms by targeting a wide array of cells (Table 1). For instance, monocytes (Mo), macrophages (MΦ) and immature dendritic cells (iDC) are attracted to sites of inflammation by defensins [12-16], where the secretion of proinflammatory cytokines by these cells is modulated, although there is still dispute to whether HNP1-3 are predominantly pro- [17,18] or anti-inflammatory [19-21]. Moreover, defensins have an impact on antigen presentation by influencing processes of differentiation: HNP1-3 was shown to inhibit M-CSF induced macrophage differentiation of monocytes [22], while maturation of iDC with upregulation of the co-stimulatory molecules CD80 and CD86 as well as MHCII is promoted by hBD3 [5,12,23].T-cells that interact with antigen-presenting cells to promote adaptive immune responses [24] are attracted by defensins [13,15,16,25]. Costimulatory molecules on T-cells (i.e., CD28) are increased in response to HNP1-3 [26,27] and the secretion of various proinflammatory peptides is promoted [26,28]. In accordance with the notion that defensins are capable of inducing the maturation/activation of antigen-presenting cells, enhanced antigen-specific humoral and cellular immune responses were found when antigen was administered in combination with HNP or mouse-homologues of beta-defensins [12,26]. Furthermore, defensins were demonstrated to inhibit the classic and lectin pathway of complement activation by binding C1q and mannose-binding lectin [29,30], they increase proliferation, migration, and proinflammatory cytokine secretion in keratinocytes [31-33], and enhance antigen-presentation and proinflammatory cytokine secretion in lung epithelial cells [27,34-36].

Our current understanding of inciting events in autoimmune disorders such as systemic lupus erythematosus or rheumatoid arthritis crucially involves presentation of autoantigens by antigen-presenting cells to T-cells which subsequently promote adaptive immune responses including the generation of autoantibodies. Furthermore, an important role is attributed to a proinflammatory cytokine milieu [50,51]. The above delineated actions of defensins on these processes render the hypothesis of their involvement in autoimmune processes plausible and were a rationale to explore their role in autoimmune rheumatic disorders. Furthermore, defensins may provide a link between adaptive immune responses to autoantigens and innate immune mechanisms in autoimmune disorders.

1.3. Rheumatoid Arthritis (RA)

RA is the most common inflammatory rheumatic disorder, affecting approximately 1% of the population and ultimately leading to destruction of joints by a chronic inflammation which affects cartilage and bone [51]. In patients with RA and other inflammatory arthritic disorders, HNP1-3 was identified in synovial fluid by spectrometry. HNP1-3 discriminated synovial fluid from patients with RA and osteoarthritis (OA) with a sensitivity of around 70% and a specificity of 56%. According to receiver operating characteristics analysis, the discriminative value was moderate (area under the curve of 66–70%) [52]. Importantly, HNP-levels in the synovial fluid were clearly higher in RA patients with erosive disease as opposed to non erosive disease in one study (4,374 ± 805 vs. 2,391 ± 946 ng/mL) [53]. Besides further suggesting a potential involvement in the pathogenesis, these findings indicate that HNP1-3 in the synovial fluid may also function as a biomarker for RA [52,53]. Interestingly, there was no correlation between synovial neutrophil counts and HNP1-3-levels in RA patients [52]. This was speculated to be attributable to an increased load of HNP1-3 in azurophilic granules, increased degranulation and apoptosis of neutrophils in synovial fluid, or to increased production of HNP1-3 by sources other than neutrophils within the RA joint [53]. Indeed, HNP1-3 is present in the synovial membrane [54,55], and was immunhistochemically located to neutrophils in, or close to the synovial layer [55]. While no significant differences in immunohistochemical stains for HNP1-3 were detected between RA and OA-synovial membranes, explanted synovial tissue of RA-patients secreted more HNP1-3 [55]. Thus, besides neutrophils in the synovial fluid, neutrophils within the synovial membrane contribute to HNP1-3 production in RA joints. Data concerning the regulation of HNP1-3 in synovial tissue is scarce. In RA synovial membranes, in contrast to tissues from OA patients, the secretion of HNP1-3 was not lowered by incubation with the proinflammatory TNFα. This was speculated to be attributable to TNFα-receptor desensitization by already high levels of TNFα present in RA. So far, there is no proof of this concept, however [55]. Although HNP1-3 levels in the synovial fluid of RA patients are clearly superior to their concentration in blood [53], HNP1-3 were identified to be upregulated in peripheral blood mononuclear cells of RA patients by mRNA micro-array analysis when compared to healthy controls [56]. This increases the attractiveness of HNP1-3 as a biomarker for RA, because peripheral blood is more easily accessible than synovial fluid. However, more studies are needed in order to establish the usefulness of HNP1-3 in distinguishing RA from relevant differential diagnoses, or to demonstrate their usefulness as a follow-up parameter to assess disease activity.

Besides defensins from neutrophils, β-defensins in joints were also described. HBD1 and hBD2 are expressed in articular cartilage and synovial membranes of joints [54,57,58]. The expression of hBD2 in chondrocytes can be induced by the proinflammatory cytokines TNFα, IL6, IL1β [58,59], which have all been strongly implied in the pathogenesis of RA [60]. In a study employing RT-PCR and immunohistochemistry of synovial membranes from 10 patients each with RA, OA, pyogenic arthritis or healthy controls, there was a tendency towards a preferential detection of hBD2 in RA [54]. Similar data exist for hBD3: although largely absent in healthy articular cartilage, hBD3 can be found in OA or RA [54,61]. Proinflammatory cytokines such as TNFα and IL1β are potential stimuli for hBD3 induction [61]. Interestingly, besides its immunomodulatory properties, hBD3 may also have a role in cartilage destruction present in RA, because it activates matrix metalloproteinases which degrade the extracellular matrix of cartilage [61,62]. Thus, hBD3 is a potential candidate for therapeutical interventions to inhibit cartilage destruction and further studies are clearly warranted.

1.4. Systemic Lupus Erythematosus (SLE)

SLE is a multisystem inflammatory autoimmune disorder characterized by autoantibodies to nuclear antigens and causing a wide variety of organ damage including glomerulonephritis and arthritis [50]. Based on the current understanding of SLE, there is reasonable ground to suspect a role for defensins in SLE pathogenesis: presentation of autoantigens by antigen-presenting cells and epithelial cells to autoreactive T-cells, apoptosis, and complement deficiency are major mechanisms driving the disease [50,63,64].

Micro-array experiments suggested an increased HNP3-gene expression in peripheral blood of SLE patients as compared to healthy controls [65,66]. This finding was later confirmed by demonstrating elevated peptide levels in two SLE patient cohorts [67,68]. Furthermore, although the subgroup analyses contained only few patients, some correlation to clinical data was suggested, including higher levels in patients with lupus nephritis, skin rash, or arthritis [67]. Moreover, disease activity measured by the SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) correlated to HNP-levels on an individual patient basis [67]. Correlations to disease activity parameters, i.e., SLEDAI and antibody-concentration to double-stranded DNA, were also observed for hBD2 [68]. Besides elevated HNP-protein levels, antibodies against HNP have been found in SLE patient sera and were elevated when compared to healthy controls. Patients with active disease (SLEDAI ≥ 6) had higher values than those in remission. In the same cohort, serial HNP-antibodies were available from two patients and were demonstrated to decline after initiation of effective therapy with glucocorticosteroids [69]. The role of these antibodies in SLE is not clear and warrants further attention. Interestingly, no β-defensin antibodies were detected in a search of over 300 patients with connective tissue disorders including SLE [70].

SLE commonly also involves the skin and leads to a variety of rashes. These manifestations may also occur separately from systemic signs of the disease [71]. Skin infections are rarely observed in patients with cutaneous lupus, even though inflammatory skin lesions may be extensive [72]. This prompted Kreuter et al. to analyze if an increase in defensin-expression may be found [72]. RT-PCR revealed that hBD1 and hBD3 were found to be significantly higher in subacute cutaneous lupus erythematodes (SCLE) than in clinically distinct subsets of the disease termed Lupus erythematosus tumidus (LET), discoid Lupus erythematosus (DLE), and in healthy controls. HBD2 was increased in SCLE and DLE when compared to healthy controls. Immunohistochemical analysis confirmed that hBD1-3 were predominantly expressed in SCLE skin. The upregulation of defensins may reflect the cytokine milieu of cutaneuous lupus with the presence of TNFα and IFNγ which upregulate hBD2 and 3-expression [72,73]. Alternatively, the distinct expression patterns in SCLE and DLE found in this study were interpreted as hints for a pathogenetical involvement of defensins in cutaneous lupus [72].

1.5. Sjögren's Syndrome (SS)

SS is an autoimmune disorder which features lymphocytic infiltration of various organs, especially exocrine glands [74]. In minor salivary glands, the expression of hBD1 and especially hBD2 was reduced when compared to control tissues as assessed by immunohistochemistry. This was surprising, because the authors initially hypothesized that increased expression of defensins would be found due to the inflammatory processes at salivary glands. It was speculated that a reduction in defensin expression might be found even before infiltration of salivary glands with lymphocytes [75], which in turn might suggest that defensin-deficiency might contribute to SS pathogenesis.

1.6. Wegener's Granulomatosis (WG)

WG (Granulomatosis with Polyangiitis [76]) is a vasculitis of small to medium sized vessels characterized by the formation of destructive granulomas in the respiratory tract and vasculitis affecting various organs such as the kidneys leading to rapid progressive glomerulonephritis [77]. Antineutrophil cytoplasmatic antibodies (ANCA) are implied in the pathogenesis of WG and can be found in 90% of patients with generalized disease [77]. Cross-linking of Fcγ-receptors by these ANCA leads to activation of neutrophils, degranulation, and HNP-release [78]. The chemotactic properties of HNPs on various leukocytes (Table 1) may then contribute to the formation of typical granulomas [78]. This model is further supported by the finding that increased serum levels of HNPs can indeed be found in WG [79]. Moreover, four patients with serious organ involvement requiring treatment with cyclophosphamid had higher HNP concentrations than WG patients without cyclophosphamid treatment. Although hampered by small patient number, this finding hints at increased values in more severe disease states. Besides HNP, hBD2, but not hBD3 was found to be increased in WG and was especially high in four patients with meningeal granulomas [79].

1.7. Behçet Disease (BD)

BD is a vasculitis which involves arteries and veins of all sizes, typically leads to mucocutaneous ulcerations and is geographically distributed along the silk route [80]. HNP1-mRNA was identified to be overexpressed in peripheral blood mononuclear cells of BD patients and the HNP1-level in blood of patients was increased when compared to healthy controls. Especially high values were found in patients with arthritis or active disease [81]. Expressional changes, but also copy number variations of individual genes (CNV) may contribute to varying defensin levels [82]. In one study, CNV of the hBD2-gene in 197 patients with BD were compared to matched controls. Although there was a tendency towards lower CN in patients, the difference was not statistically significant and there was no correlation to clinical data. The authors thus concluded that CNV of the hBD2-gene do not contribute to the pathogenesis of BD [83]. This does not exclude the contribution of hBD2 in BD altogether, however, because CNV are not the only determinate for levels of biologically active peptides [82].

1.8. Microscopic Polyangiitis (MPA)

MPA is a necrotizing vasculitis of small vessels with predominantly pulmonary and renal involvement. Antineutrophil cytoplasmatic antibodies with perinuclear staining in indirect immunofluorenscence assays is noted in the majority of patients [84]. The target antigen of these antibodies most commonly is myeloperoxidase. Another potential target for ANCAs are HNPs because they are predominantly present in neutrophil granulocytes. Indeed, elevated HNP-ANCA were described in MPA [69]. The function of these antibodies is unknown, however. Conversely, no ANCA to hBD1 or hBD2 were detected in sera of patients with ANCA-associated vasculitis [70], reflecting that alpha but not beta defensins are preferentially expressed by neutropils.

1.9. Sarcoidosis

Sarcoidosis is a systemic disorder characterized by a non-caseating granulomatous inflammation which can affect virtually any organ, including lung, joints and skin [85]. In broncheoalveolar lavage fluid of sarcoidosis patients, HNP-levels were increased approximately 10-fold. Moreover, patients with stage II or III disease had higher values than patients suffering from stage I [86]. Interestingly, alveolar macrophages of sarcoidosis patients released more TNFα than alveolar macrophages of control patients when stimulated with HNP. The authors thus concluded that HNP may have a role in sustaining pulmonary inflammation in sarcoidosis [86].

1.10. Cardiovascular Morbidity in Rheumatic Diseases and Defensins

Patients with autoimmune disorders are known to suffer from an increased cardiovascular morbidity which is not completely attributable to a higher burden of cardiovascular risk factors. Disease inherent mechanisms and a chronic systemic inflammation are thought to contribute to the observed effects [87]. In this context, it is interesting to note that defensins have recently been linked to atherosclerosis. HBD2 was shown to possess angiogenetic properties similar to vascular endothelial growth factor, as demonstrated by the ability to induce tube formation of HUVEC cells in a matrigel-assay. Furthermore, endothelial cells proliferate in the presence of hBD2, albeit to a lesser extent than in response to VEGF. Of note, the mechanisms of action are distinct from VEGF and at least in part mediated via the vitronectin receptor avβ3 [46]. Beyond in vitro experiments, there is clinical proof of concept: In a cohort of SLE patients, baseline hBD2 values were higher in patients experiencing cardiovascular events during follow-up and hBD2 was of additional benefit to traditional cardiovascular risk factors in predicting cardiovascular events in the cohort (unpublished data). HNPs also confer endothelial cell dysfunction and are increased in atherosclerotic plaques [88]. In a clinical study, the risk of cardiovascular mortality in patients with intermittent claudication who had HNP-levels in the upper tertile was shown to be elevated threefold. When highly sensitive CRP-values were combined into a model also incorporating HNP-values, predictions for cardiovascular mortality could be achieved with a moderate discrimination (area under the curve in receiver operating characteristics analysis of 0.71) [89].

2. Conclusions

Over recent years, it has become increasingly clear that defensins take part in innate and adaptive immune responses. Their immunomodulatory actions provide the rationale for the assumption that they play a role in autoimmune diseases. Increasingly accumulating evidence has indicated that defensins are involved in autoimmune disorders which makes them an interesting target for drug or biomarker development. However, direct mechanistic proof of their actions in the pathogenesis of autoimmune disorders is largely lacking. Future challenges in this area involve the exploration of defensin-actions in animal models of autoimmune disease, including targeted interventions and gene-silencing experiments.

Table
Table 1. Immunomodulatory functions of human defensins.
Table 1. Immunomodulatory functions of human defensins.
TargetImmunomodulatory ActionDefensinsRef.
Moincrease of TNFα and IL1β release from stimulated cellsHNP1-3[17]
inhibition of IL1β release from stimulated cellshD5, HN P1[21]
inhibition of M-CSF induced macrophage differentiationHNP1-3[22]
chemotaxishBD1-4, HNP1-3[37-40]
MΦinhibition of TNFα, IL8, IL6, IL1β and NO releaseHNP1-3, hBD3[19,20]
increase of TNFα and IFNγ releaseHNP1-3[18]
enhancement of phagocytosisHNP1-3[18]
chemotaxishBD1-4, HNP1, -3, hD5[13,14,39]
iDCmaturation (upregulation of CD40, CD80, CD86, MHCII)hBD3[5,12,23]
chemotaxishBD2-3, HNP[12,15,16,39]
granulocytesAnti-chemotacticHNP1[41]
Chemotactic for TNFα activated cellshBD2[31]
inhibition of apoptosishBD3[42]
mast cellsIncrease of mast cell degranulationhBD2[43,44]
chemotaxisHNP1-3, hD5, hBD1-4[14,44]
T-cellsIncrease of IFNγ, TNFα, IL10, IL1β, IL6, and IL22, inhibition of IL17 secretionhBD2[26,28]
increase of CD28, CD11a, decrease/increase of CTLA4HNP[26,27]
lung epithelial cellsincrease apoptosis dose dependentlyHNP1, hBD2[35,36,45]
increase IL8, IL1β, MCP1HNP1[34-36]
enhancing antigen-presentation (upregulation of CD54, CD80, CD86)HNP1-3[27]
endothelial cellsstimulation of angioneogenesishBD2[46]
COX2 and endothelin-1 production increasedHNP[47]
inhibition of TNFα-mediated upregulation of VCAM1 > ICAM1HNP[17]
Keratinocytesincrease of IL1β, IL6, IL10, IP10, MCP1, MIP3α, RANTES, IL18hBD2-4[31-33]
increase of migration and proliferationhBD2-4[31]
fibroblasts/epitheliaincrease in proliferation, dose-dependent cytotoxicityHNP1[48]
complementinhibition of classical and lectin pathway by binding to C1q and MBLHNP1[29,30]
miscellaneousinhibition of T-cell response by competetive binding to MHC-moleculesHNP1-2[49]
enhancing antigen-specific humoral and cellular immune responseHNP[12,26]

Legend: Monocyte (Mo), Macrophage (MΦ), Tumor necrosis factor α (TNFα), immature dendritic cells (iDC), Interleukin (IL), macrophage-colony-stimulating-factor (M-CSF), Interferon (IFN), Cluster of differentiation (CD), Major Histocompatibility Complex (MHC), Cytotoxic T-Lymphocyte Antigen (CTLA), Monocyte Chemotactic Protein (MCP), Cyclooxygenase (COX), Vascular Cell Adhesion Molecule (VCAM), Inter-Cellular Adhesion Molecule (ICAM), Macrophage inflammatory protein (MIP), Regulated upon Activation, Normal T-cell Expressed, and presumably Secreted (RANTES), mannose binding lectin (MBL).

Acknowledgments

S. V. gratefully acknowledges support by grants from the “Hiller-Stiftung” and from the Medical Faculty of Heinrich-Heine-University Düsseldorf.

References

  1. Schneider, J.J.; Unholzer, A.; Schaller, M.; Schäfer-Korting, M.; Korting, H.C. Human defensins. J. Mol. Med. 2005, 83, 587–595. [Google Scholar]
  2. Yang, D.; Biragyn, A.; Hoover, D.M.; Lubkowski, J.; Oppenheim, J.J. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxins in host defense. Annu. Rev. Immunol. 2004, 22, 181–215. [Google Scholar]
  3. Hazlett, L.; Wu, M. Defensins in innate immunity. Cell Tissue Res. 2011, 343, 175–188. [Google Scholar]
  4. Wiesner, J.; Vilcinskas, A. Antimicrobial peptides: The ancient arm of the human immune system. Virulence 2010, 1, 440–464. [Google Scholar]
  5. Yang, D.; Liu, Z.-H.; Tewary, P.; Chen, Q.; de la Rosa, G.; Oppenheim, J.J. Defensin participation in innate and adaptive immunity. Curr. Pharm. Des. 2007, 13, 3131–3139. [Google Scholar]
  6. Schutte, B.C.; McCray, P.B. Beta-defensins in lung host defence. Annu. Rev. Physiol. 2002, 64, 709–748. [Google Scholar]
  7. Vordenbäumen, S.; Pilic, D.; Otte, J.-M.; Schmitz, F.; Schmidt-Choudhury, A. Defensins are differentially expressed with respect to the anatomic region in the upper gastrointestinal tract of children. J. Pediatr. Gastroenterol. Nutr. 2009, 49, 139–142. [Google Scholar]
  8. Rehaume, L.M.; Hancock, R.E. Neutrophil-derived defensins as modulators of innate immune function. Crit. Rev. Immunol. 2008, 28, 185–200. [Google Scholar]
  9. Jones, D.E.; Bevins, C.L. Paneth cells of the human small intestine express an anitmicrobial peptide gene. J. Biol. Chem. 1992, 32, 23216–23225. [Google Scholar]
  10. Franco, O.L. Peptide promiscuity: An evolutionary concept for plant defense. FEBS Lett. 2011, 585, 995–1000. [Google Scholar]
  11. Yang, D.; Chertov, O.; Oppenheim, J.J. Participation of mammalian defensins and cathelicidins in anti-microbial immunity: Receptor and activities of human defensins and cathelicidin (LL-37). J. Leukocyte Biol. 2001, 69, 691–697. [Google Scholar]
  12. Biragyn, A.; Surenhu, M.; Yang, D.; Ruffini, P.A.; Haines, B.A.; Klyushnenkova, E.; Oppenheim, J.J.; Kwak, L.W. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antiges. J. Immunol. 2001, 167, 6644–6653. [Google Scholar]
  13. Grigat, J.; Soruri, A.; Forssmann, U.; Riggert, J.; Zwirner, J. Chemoattraction of macrophages, T lymphocytes and mast cells is evolutionarily conserved within the human alpha-defensin family. J. Immunol. 2007, 179, 3958–3956. [Google Scholar]
  14. Soruri, A.; Grigat, J.; Forssmann, U.; Riggert, J.; Zwirner, J. Beta-defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved. Eur. J. Immunol. 2007, 37, 2474–2486. [Google Scholar]
  15. Yang, D.; Chen, Q.; Chertov, O.; Oppenheim, J.J. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukocyte. Biol. 2000, 68, 9–14. [Google Scholar]
  16. Yang, D.; Chertov, O.; Bykoskaia, S.N.; Chen, Q.; Buffo, M.J.; Shogan, J.; Anderson, M.; Schröder, J.-M.; Wang, J.M.; Howard, O.M.Z.; Oppenheim, J.J. Beta-defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286, 525–528. [Google Scholar]
  17. Chaly, Y.V.; Paleolog, E.M.; Kolesnikova, T.S.; Tikhonov, I.I.; Petratchenko, E.V.; Voitenko, N.N. Neutrophil a-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur. Cytokine Netw. 2000, 11, 257–266. [Google Scholar]
  18. Soehnlein, O.; Kai-Larsen, Y.; Frithiof, R.; Sorensen, S.F.; Kenne, E.; Scharffetter-Kochanek, K.; Eriksson, E.E.; Herwald, H.; Agerberth, B.; Lindbom, L. Neutrophil primary granule proteine HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages. J. Clin. Invest. 2008, 118, 3491–3502. [Google Scholar]
  19. Miles, K.; Clarke, D.J.; Lu, W.; Sibinska, Z.; Beaumont, P.E.; Davidson, D.J.; Barr, T.A.; Campopiano, D.J.; Gray, M. Dying and necrotic neutrophils are anti-inflammatory secondary to the release of alpha-defensins. J. Immunol. 2009, 183, 2122–2132. [Google Scholar]
  20. Semple, F.; Webb, S.; Li, H.-N.; Patel, H.B.; Perretti, M.; Jackson, I.J.; Gray, M.; Davidson, D.J.; Dorin, J.R. Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. J. Immunol. 2010, 40, 1073–1078. [Google Scholar]
  21. Shi, J.; Aono, S.; Lu, W.; Ouellette, A.J.; Hu, X.; Ji, Y.; Wang, L.; Lenz, S.; van Ginkel, F.W.; Liles, M.; Dykstra, C.; Morrison, E.E.; Elson, C.E. A novel role for defensins in intestinal homeostasis: Regulation of IL1b secretion. J. Immunol. 2007, 179, 1245–1253. [Google Scholar]
  22. Droin, N.; Jacquel, A.; Hendra, J.-B.; Racoeur, C.; Truntzer, C.; Pecqueur, D.; Benikhlef, N.; Ciudad, M.; Guery, L.; Jooste, V.; Dufour, E.; Fenaux, P.; Quesnel, B.; Kosmider, O.; Fontenay, M.; Ducoroy, P.; Solary, E. Alpha-defensins secreted by dysplastic granulocytes inhibit the differntiation of monocytes in chronic myelomonocytic leukemia. Blood 2009, 115, 78–88. [Google Scholar]
  23. Funderburg, N.; Lederman, M.M.; Feng, Z.; Drage, M.G.; Jadlowsky, J.; Harding, C.V.; Weinberg, A.; Sieg, S.F. Human beta-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc. Natl. Acad. Sci. USA 2007, 104, 18631–18635. [Google Scholar]
  24. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 329, 245–252. [Google Scholar]
  25. Chertov, O.; Michiel, D.F.; Xu, L.; Wang, J.M.; Tani, K.; Murphy, W.J.; Longos, D.L.; Taub, D.D.; Oppenheim, J.J. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from intereukin-8-stimulated neutrophils. J. Biol. Chem. 1996, 271, 2935–2940. [Google Scholar]
  26. Lillard, J.W.; Boyaka, P.N.; Chertov, O.; Oppenheim, J.J.; McGhee, J.R. Mechanisms for induction of acquired host immunity by neutrohil peptide defensins. Natl. Acad. Sci. USA 1999, 96, 651–656. [Google Scholar]
  27. Vaschetto, R.; Grinstein, J.; Del Sorbo, L.; Khine, A.A.; Voglis, S.; Tullis, E.; Slutsky, A.S.; Zhang, H. Role of human neutrophil peptides in the intitial interaction between lung epithelial cells and CD4+ lymphocytes. J. Leukocyte Biol. 2007, 81, 1022–1031. [Google Scholar]
  28. Kanda, N.; Kamata, M.; Tada, Y.; Ishikawa, T.; Sato, S.; Watanabe, S. Human beta-defensin-2 enhances IFN-gamma and IL-10 production and suppresses IL-17 production in T-cells. J. Leukocyte Biol. 2011, 89, 935–944. [Google Scholar]
  29. Groeneveld, T.W.L.; Ramwadhoebé, T.H.; Trouw, L.A.; van den Ham, D.L.; van der Borden, V.; Drijfhout, J.W.; Hiemstra, P.S.; Daha, M.R.; Roos, A. Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation. Mol. Immunol. 2007, 44, 3608–3614. [Google Scholar]
  30. van den Berg, R.H.; Faber-Krol, M.C.; van Wetering, S.; Hiemstra, P.S.; Daha, M.R. Inhibition of activation of the classical pathway of complement by human neutrophil defensins. Blood 1998, 92, 3898–3903. [Google Scholar]
  31. Niyonsaba, F.; Ogawa, H.; Nagaoka, I. Human beta-defensin-2 functions as a chemotactic agent for tumor necrosis factor-alpha treated human neutrophils. Immunology 2004, 111, 273–281. [Google Scholar]
  32. Niyonsaba, F.; Ushio, H.; Nagaoka, I.; Okumura, K.; Ogawa, H. The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 ERK MAPK activation in primary human keratinocytes. J. Immunol. 2005, 175, 1776–1784. [Google Scholar]
  33. Niyonsaba, F.; Ushio, H.; Nakano, N.; Ng, W.; Sayama, K.; Hashimoto, K.; Nagaoka, I.; Okumura, K.; Ogawa, H. Epidermal keratinocyte migration, prolideration and production of proinflammatory cytokines and chemokines. J. Invest. Dermatol. 2007, 127, 594–604. [Google Scholar]
  34. Khine, A.A.; Del Sorbo, L.; Vaschetto, R.; Voglis, S.; Tullis, E.; Slutsky, A.S.; Downey, G.P.; Zhang, H. Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway. Blood 2006, 107, 2936–2942. [Google Scholar]
  35. Sakamoto, N.; Mukae, H.; Fujii, T.; Ishii, H.; Yoshioka, S.; Kakugawa, T.; Sugiyama, K.; Mizuta, Y.; Kadota, J.; Nakazato, M.; Kohno, S. Differential effects of alpha- and beta-defensin on cytokine production by cultures human bronchial epithelial cells. Am. J. Phys. Lung Cell Mol. Phys. 2004, 288, L508–L513. [Google Scholar]
  36. van Wetering, S.; Mannesse-Lazeroms, S.P.G.; Dijkman, J.; Hiemstra, P.S. Effect of neutrophil serine proteinases and defensins on lung epithelial cells: Modulation of cytotoxicity and IL-8 production. J. Leukocyte Biol. 1997, 62, 217–226. [Google Scholar]
  37. Garcia, J.R.; Jaumann, F.; Schulz, S.; Krause, A.; Rodriguez-Jiminez, J.; Forssmann, U.; Adermann, K.; Klüver, E.; Vogelmeier, C.; Becker, D.; Hedrich, R.; Forssmann, W.G.; Bals, R. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res. 2001, 306, 257–264. [Google Scholar]
  38. Garcia, J.R.; Krause, A.; Schulz, S.; Rodriguez-Jiminez, J.; Klüver, E.; Adermann, K.; Forssmann, U.; Frimpong-Boateng, A.; Bals, R.; Forssmann, W.G. Human beta-defensin 4: A novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J. 2001, 15, 1819–1821. [Google Scholar]
  39. Röhrl, J.; Yang, D.; Oppenheim, J.J.; Hehlgans, T. human b-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. J. Immunol. 2010, 184, 6688–6694. [Google Scholar]
  40. Territo, M.C.; Ganz, T.; Selsted, M.E.; Lehrer, R. Monocyte-chemotactic activity of defensins from human neutrohils. J. Clin. Invest. 1989, 84, 2017–2020. [Google Scholar]
  41. Grutkoski, P.S.; Graeber, C.T.; Lim, Y.P.; Ayala, A.; Simms, H.H. Alpha-defensin 1 (human neutrophil protein 1) as an antichemotactic agent for human polymorphonuclear leukocytes. Antimicrob. Agents Chemother 2003, 47, 2666–2668. [Google Scholar]
  42. Nagaoka, I.; Niyonsaba, F.; Tsutsumi-Ishii, Y.; Tamura, H.; Hirata, M. Evaluation of the effect of human beta-defensin on neutrophil apoptosis. Int. Immunol. 2008, 20, 543–554. [Google Scholar]
  43. Chen, X.; Niyonsaba, F.; Ushio, H.; Hara, M.; Yokoi, H.; Matsumoto, N.; Saito, S.; Nagaoka, I.; Ikeda, S.; Okomura, K.; Ogawa, H. Antimicrobial peptides human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. Eur. J. Immunol. 2007, 37, 434–444. [Google Scholar]
  44. Niyonsaba, F.; Iwabuchi, K.; Matsuda, H.; Ogawa, H.; Nagaoka, I. Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxim-sensitive and phospholipase C-dependent pathway. Int. Immunol. 2002, 14, 421–426. [Google Scholar]
  45. Liu, C.-Y.; Lin, H.-C.; Yu, C.-T.; Lin, S.-M.; Lee, K.-Y.; Chen, H.-C.; Chou, C.-L.; Huang, C.-D.; Chou, P.-C.; Liu, W.-T.; Wang, C.-H.; Kuo, H.-P. The concentraiton-dependent chemokine release and pro-apoptotic effects of neutrophil-derived alpha-defensin-1 on human bronchial and alveolar epithelial cells. Life Sci. 2007, 80, 749–758. [Google Scholar]
  46. Baroni, A.; Donnarumma, G.; Paoletti, I.; Longanesi-Cattani, I.; Bifulco, K.; Tufano, M.A.; Carriero, M.V. Antimicrobial human beta-defensin-2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cells. Peptides 2009, 30, 267–272. [Google Scholar]
  47. Syeda, F.; Tullis, E.; Slutsky, A.S.; Zhang, H. Human neutrophil peptides upregulate expression of COX-2 and endothelin-1 by inducing oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H2769–H2774. [Google Scholar]
  48. Nishimura, M.; Abiko, Y.; Kurashige, Y.; Takeshima, M.; Yamazaki, M.; Kusano, K.; Saitoh, M.; Nakashima, N.; Inoue, T.; Kaku, T. Effect of defensin peptides on eukaryotic cells: Primary epithelial cell, fibroblasts and squamous cell carcinoma cell lines. J. Dermatol. Sci. 2004, 36, 87–95. [Google Scholar]
  49. Halder, T.M.; Blüggel, M.; Heinzel, S.; Pawelec, G.; Meyer, H.E.; Kalbacher, H. Defensins are dominant HLA-DR-associated self-peptides from CD34− peripheral blood mononuclear cells of different tumor patients. Blood 2000, 95, 2890–2896. [Google Scholar]
  50. Rahman, A.; Isenberg, D.A. Systemic lupus erythematosus. N. Engl. J. Med. 2008, 358, 929–939. [Google Scholar]
  51. Smith, J.B.; Haynes, M.K. Rheumatoid arthritis—a molecular understanding. Ann. Intern. Med. 2002, 136, 908–922. [Google Scholar]
  52. Baillet, A.; Trocmé, C.; Berthier, S.; Arlotto, M.; Grange, L.; Chenau, J.; Quétant, S.; Sève, M.; Berger, F.; Juvin, R.; Morel, F.; Gaudin, P. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology (Oxford) 2010, 49, 671–682. [Google Scholar]
  53. Bokarewa, M.I.; Jin, T.; Tarkowski, A. Intraarticular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis. J. Rheumatol 2003, 30, 1719–1724. [Google Scholar]
  54. Paulsen, F.; Pufe, T.; Conradi, L.; Varoga, D.; Toskos, M.; Papendieck, J.; Petersen, W. Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membrane. J. Pathol. 2002, 198, 369–377. [Google Scholar]
  55. Riepl, B.; Grässel, S.; Wiest, R.; Fleck, M.; Straub, R.H. Tumor necrosis factor and norepinephrine lower the levels of human neutrophil peptides 1-3 secretion by mixed synovial tissue cultures in osteoarthritis and rheumatois arthritis. Arthrit. Res. Ther. 2010. [Google Scholar] [CrossRef]
  56. Bovin, L.F.; Rieneck, K.; Workman, C.; Nielsen, H.; Sorensen, S.F.; Skjodt, H.; Florescu, A.; Brunak, S.; Bendtzen, K. Blood cell gene expression profiling in rheumatoid arthritis: Discriminative genes and effect of rheumatoid factor. Immunol. Lett. 2004, 93, 217–226. [Google Scholar]
  57. Paulsen, F.; Pufe, T.; Petersen, W.; Tillmann, B. Expression of natural peptide antibiotics in human articular cartilage and synovial membrane. Clin. Diag. Lab. Immunol. 2001, 8, 1021–1023. [Google Scholar]
  58. Varoga, D.; Pufe, T.; Harder, J.; Meyer-Hoffert, U.; Mentlein, R.; Schröder, J.-M.; Petersen, W.J.; Tillmann, B.N.; Proksch, E.; Goldring, M.B.; Paulsen, F.P. Production of endogenous antibiotics in articular cartilage. Arthrit. Rheum. 2004, 50, 3526–3534. [Google Scholar]
  59. Varoga, D.; Paulsen, F.P.; Kohrs, S.; Grohmann, S.; Lippross, S.; Mentlein, R.; Tillmann, B.; Goldring, M.B.; Besch, L.; Pufe, T. Expression and regulation of human beta-defensin-2 in osteoarthritis cartilage. J. Pathol. 2006, 209, 166–173. [Google Scholar]
  60. Smolen, J.S.; Aletaha, D.; Koeller, M.; Weisman, M.H.; Emery, P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370, 1861–1874. [Google Scholar]
  61. Varoga, D.; Pufe, T.; Harder, J.; Schröder, J.-M.; Mentlein, R.; Meyer-Hoffert, U.; Goldring, M.B.; Tillmann, B.; Hassenpflug, J.; Paulsen, F. Human beta-defensin 3 mediates tissue remodeling processes in articular cartilage by increasing levels of metalloproteinases and reducing levels of their endogenous inhibitors. Arthrit. Rheum. 2005, 52, 1736–1745. [Google Scholar]
  62. Varoga, D.; Pufe, T.; Mentlein, R.; Kohrs, S.; Grohmann, S.; Tillmann, B.; Hassenpflug, J.; Paulsen, F. Expression and regulation of antimicrobial peptides in articular joints. Ann. Anat. 2005, 187, 499–508. [Google Scholar]
  63. Cook, H.T.; Botto, M. Mechanisms of disease: The complement system and the pathogenesis of systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2006, 2, 330–337. [Google Scholar]
  64. Seery, J.P. IFN-g transgenic mice: Clues to the pathogenesis of systemic lupus erythematosus? Arthrit. Res. 2000, 2, 437–440. [Google Scholar]
  65. Bennett, L.; Palucka, A.K.; Arce, E.; Cantrell, V.; Borvak, J.; Banchereau, J.; Pacual, V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003, 197, 711–723. [Google Scholar]
  66. Ishii, T.; Onda, H.; Tanigawa, A.; Oshishima, S.; Fujiwara, H.; Mima, T.; Katada, Y.; Degushi, H.; Suemura, M.; Miyake, T.; Miyatake, K.; Kawase, I.; Zhao, H.; Tomiyama, Y.; Saeki, Y.; Nojima, H. Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients. DNA Res. 2005, 12, 429–439. [Google Scholar]
  67. Sthoeger, Z.M.; Bezalel, S.; Chapnik, N.; Asher, I.; Froy, O. High alpha-defensin levels in patients with systemic lupus erythematosus. Immunology 2009, 127, 116–122. [Google Scholar]
  68. Vordenbäumen, S.; Fischer-Betz, R.; Timm, D.; Sander, O.; Chehab, G.; Richter, J.; Bleck, E.; Schneider, M. Elevated levels of human beta-defensin 2 (hBD2) and human neutrophil peptides (HNP) in systemic lupus erythematosus. Lupus 2010, 19, 1648–1653. [Google Scholar]
  69. Tamiya, H.; Tani, K.; Miyata, J.; Sato, K.; Urata, T.; Lkhagvaa, B.; Otsuka, S.; Shigekiyo, S.; Sone, S. Defensin- and cathepsin G-ANCA in systemic lupus erythematosus. Rheumatol. Int. 2006, 27, 147–152. [Google Scholar]
  70. Schultz, H.; Csernok, E.; Herlyn, K.; Reichel, P.H.; Moosig, F.; Cornely, O.A.; Fagerhol, M.K.; Gross, W.L. ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: Prevalence and clinical associations. Clin. Exp. Immunol. 2003, 21, 117–120. [Google Scholar]
  71. Walling, H.; Sontheimer, R. Cutaneous lupus erythematosus: Issues in diagnosis and treatment. Am. J. Clin. Dermatol. 2009, 10, 365–381. [Google Scholar]
  72. Kreuter, A.; Jaouhar, M.; Skrygan, M.; Tigges, C.; Stücker, M.; Altmeyer, P.; Gläser, R.; Gambichler, T. Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 2011, 65, 125–133. [Google Scholar]
  73. Wenzel, J.; Zahn, S.; Tüting, T. Pathogenesis of cutaneous lupus erythematosus: Common and different features in distinct subsets. Lupus 2010, 19, 1020–1028. [Google Scholar]
  74. Ng, W.; Bowman, S.J. Primary Sjogren's syndrome: Too dry and too tired. Rheumatology (Oxford) 2010, 49, 844–853. [Google Scholar]
  75. Kaneda, Y.; Yamaai, T.; Mizukawa, N.; Nagatsuka, H.; Yamachika, E.; Gunduz, M.; Sawaki, K.; Yamanishi, Y.; Matsubara, M.; Katase, N.; Takagi, S. Localization of antimicrobial peptides human beta-defensins in minor salivary glands with Sjögren's syndrome. Eur. J. Oral Sci. 2009, 117, 506–510. [Google Scholar]
  76. Falk, R.J.; Gross, W.L.; Guillevin, L.; Hoffman, G.S.; Jayne, D.R.; Jennette, J.C.; Kallenberg, C.G.; Luqmani, R.; Mahr, A.D.; Matteson, E.L.; Merkel, P.A.; Specks, U.; Watts, R.A. Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. Arthrit. Rheum. 2011, 63, 587–588. [Google Scholar]
  77. Schilder, A.M. Wegener's granulomatosis vasculitis and granuloma. Autoimmun. Rev. 2010, 9, 483–487. [Google Scholar]
  78. Tanaka, S.; Edberg, J.C.; Chatham, W.; Fassina, G.; Kimberly, R.P. Fc(gamma)RIIIb allele-sensitive release of alpha-defensins: Anti-neutrophile cytoplasmic antibody-induced release of chemotaxins. J. Immunol. 2003, 171, 6090–6096. [Google Scholar]
  79. Vordenbäumen, S.; Timm, D.; Bleck, E.; Richter, J.; Fischer-Betz, R.; Chehab, G.; Sander, O.; Schneider, M. Altered serum levels of human neutrophil peptides (HNP) and human beta-defensin 2 (hBD2) in Wegener's granulomatosis. Rheumatol. Int. 2010. [Google Scholar] [CrossRef]
  80. Kaneko, F.; Togashi, A.; Saito, S.; Sakuma, H.; Oyama, N.; Nakamura, K.; Yokata, K.; Oguma, K. Behcet's disease (Adamantiades-Behcet's disease). Clin. Dev. Immunol. 2011. [Google Scholar] [CrossRef]
  81. Ahn, J.K.; Hwang, J.W.; Oh, J.M.; Bae, E.K.; Lee, J.; Lee, Y.S.; Kohn, E.M.; Cha, H.S. Increase alpha-defensin-1 expression in Korean patients with Behcet's disease. Joint Bone Spine 2011. [Google Scholar] [CrossRef]
  82. Groth, M.; Wiegand, C.; Szafranski, K.; Huse, K.; Kramer, M.; Rosenstiel, P.; Schreiber, S.; Norgauer, J.; Platzer, M. Both copy number and sequence variations affect expression of human DEFB4. Genes Immun. 2010, 11, 458–466. [Google Scholar]
  83. Park, J.J.; Oh, B.R.; Kim, J.Y.; Park, J.A.; Kim, C.; Lee, Y.J.; Song, Y.W.; Armour, J.A.; Lee, E.B. Copy number variation of beta-defensin genes in Behcet's disease. Clin. Exp. Rheumatol. 2011. [Google Scholar] [CrossRef]
  84. Chung, S.A.; Seo, P. Microscopic polyangiitis. Rheum. Dis. Clin. North Am. 2010, 36, 545–558. [Google Scholar]
  85. Sweiss, N.J.; Patterson, K.; Sawaqed, R.; Jabbar, U.; Korsten, P.; Hogarth, K.; Wollman, R.; Garcia, J.G.; Niewold, T.B.; Baughman, R.P. Rheumatologic manifestations of sarcoidosis. Semin. Respir. Crit. Care Med. 2010, 31, 463–473. [Google Scholar]
  86. Paone, G.; Lucantoni, G.; Leone, A.; Graziano, P.; Gasbarra, R.; Galluccio, G.; D'Antoni, S.; Puglisi, G.; Giradi, E.; Schmid, G. Human neutrophil peptides stimulate tumor necrosis factor-alpha release by alveolar macrophages from patients with sarcoidosis. Chest 2009, 135, 586–587. [Google Scholar]
  87. Vordenbäumen, S.; Schinner, S.; Halle, M.; Fischer-Betz, R.; Schneider, M. Therapy of dyslipidemia in rheumatic diseases. Z. Rheumatol. 2010, 69, 689–692. [Google Scholar]
  88. Ionita, M.G.; van den Borne, P.; Catanzariti, L.M.; Moll, F.L.; de Vries, J.P.; Pasterkamp, G.; Vink, A.; de Kleijn, D.P. High neutriophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1842–1848. [Google Scholar]
  89. Urbonaviciene, G.; Frystyk, J.; Flyvbjerg, A.; Urbonavicius, S.; Henneberg, E.W.; Lindholt, J.S. Markers of inflammation in relation to long-term cardiovascular mortality in patients with lower-extremity peripheral arterial disease. Int. J. Cardiol. 2010. [Google Scholar] [CrossRef]

Share and Cite

MDPI and ACS Style

Vordenbäumen, S.; Schneider, M. Defensins: Potential Effectors in Autoimmune Rheumatic Disorders. Polymers 2011, 3, 1268-1281. https://doi.org/10.3390/polym3031268

AMA Style

Vordenbäumen S, Schneider M. Defensins: Potential Effectors in Autoimmune Rheumatic Disorders. Polymers. 2011; 3(3):1268-1281. https://doi.org/10.3390/polym3031268

Chicago/Turabian Style

Vordenbäumen, Stefan, and Matthias Schneider. 2011. "Defensins: Potential Effectors in Autoimmune Rheumatic Disorders" Polymers 3, no. 3: 1268-1281. https://doi.org/10.3390/polym3031268

Article Metrics

Back to TopTop